Renal dysfunction in multiple myeloma: pathogenesis, diagnosis, and pharmacist-led care strategies
NCODA Oncology and Hematology Meeting Abstracts · 15.06.2026
DOI: 10.67209/ifmf1317 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 15.06.2026. Verfasst von Azhar Hussain und 3 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben.
Abstract (Originalsprache)
Multiple myeloma (MM) is the second most common hematologic malignancy in high-income countries, accounting for approximately 17% of hematologic cancers. MM incidence has increased by 143% since 1975, and up to 50% of patients present with renal impairment at diagnosis. The American Cancer Society estimates that 36,110 new cases of MM will occur in the United States of America this year, resulting in 12,030 deaths. Renal dysfunction complicates treatment and independently worsens prognosis, emphasizing the importance of prompt intervention for optimal outcomes.
Zitieren
APA
Hussain, A., Moniot, J., Sumaya, M., & Hughes, D. M. (2026). Renal dysfunction in multiple myeloma: pathogenesis, diagnosis, and pharmacist-led care strategies. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/ifmf1317
Vancouver
Hussain A, Moniot J, Sumaya M, Hughes DM. Renal dysfunction in multiple myeloma: pathogenesis, diagnosis, and pharmacist-led care strategies. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/ifmf1317
BibTeX
@article{Hussain2026,
author = {Hussain, Azhar and Moniot, Jack and Sumaya, Mohsena and Hughes, David M},
title = {Renal dysfunction in multiple myeloma: pathogenesis, diagnosis, and pharmacist-led care strategies},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
doi = {10.67209/ifmf1317}
}
EUVIMED